Pharmaceuticals company Caplin Point Laboratories announced H1FY25 & Q2FY25 results Gross Margin for Q2FY25 is 60.9% vs 60.0% in Q2FY24 and H1FY25 is 60.3% vs 57.4% in H1FY24, aided by new product launches across existing and new markets. EBITDA Margin for Q2FY25 is steady at 36.8% vs 36.7% in Q2FY24 and H1FY25 is 36.3 % vs 35.4% in H1FY24. Basic EPS increased by 16.6% to Rs 33.54 in H1FY25 compared to Rs 28.75 in H1FY24. Cash Flow from Operations in H1FY25 is Rs 186 crore vs Rs 129 crore in H1FY24. Free Cash Flow is Rs 109 crore (after Capex investment of Rs 77 crore) in H1FY25 as compared to Rs 50 crore (after capex investment of Rs 79 crore) in H1FY24. Geographical revenue composition between Latin America & Rest of World and US for H1FY25 is in the range of 82% and 18% respectively. CSL's revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for H1FY25 in the range of 75% and 25% respectively. As of Q2FY25, Inventories are at Rs 327 crore - 50% Stock at the warehouses, close to the customer; In Transit 20%; 30% in India. Receivables is at 118 days. As of Q2FY25 Free Cash reserves are at Rs 1,039 crore and Total Liquid Assets at Rs 1,984 crore. C.C. Paarthipan, Chairman, Caplin Point Laboratories, said: Consistency and Stability are key factors in the sustainability of any business. When we add our unique business model of taking the road less travelled and catering to the bottom of the pyramid, you have a potent combination. Our relentless focus towards high degree of compliance, supply chain efficiency and robustness in cashflows has led to another strong quarter, driven both by our Emerging Markets business in LatAm and our growing business in the US. We remain confident of keeping up these fundamentals in the years to come. Result PDF
Pharmaceuticals company Caplin Point Laboratories announced Q1FY25 results: Gross Margin for Q1FY25 is 59.6% vs 55.3% in Q1FY24. EBITDA Margin for Q1FY25 is 35.7% vs 34.0% in Q1FY24, aided by new product launches. Basic EPS increased by 19.8% to Rs 16.32 in Q1FY25 compared to Rs 13.62 in Q1FY24. Cash Flow from Operations in Q1FY25 is Rs 96 crore (EBITDA to Cashflow conversion of 56.4%). Free Cash Flow is Rs 59 crore (after Capex investment of Rs 37 Crores) in Q1FY25 as compared to Rs 37 crore (after capex investment of Rs 51 Crores) in Q1FY24. Geographical revenues: Latin America and Rest of World 83%, US 17%. Caplin Steriles Ltd (“CSL”) Q1FY25 Operating Revenue is at Rs 77.93 crore, with 68.9% Y-o-Y growth. CSL's revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for Q1FY25 in the range of 74% and 26% respectively. As of 30th June 2024, Inventories are at Rs 311.60 crore, Receivables is at 113 days. Free Cash Reserves are at Rs 969.2 crore. Total Liquid Assets of the Company (Inventory + Receivables + Free Cash Reserves) are at Rs 1,849 crore as on 30th June’ 2024 Commenting on the performance, C.C. Paarthipan, Chairman said: Our company continues to be an outlier, whether its taking the road less travelled in Latin America, or focusing on our Cashflow and Bottom line rather than unsustainable or inconsistent top line growth. We’re pleased to report yet another strong set of numbers for this quarter. LatAm is a key driver of growth but we’re now also supported by strong performance from the US. As we embark on launching our own frontend in the US, we remain confident that our pattern of success through taking the road less travelled would repeat itself in the biggest markets in the world as well. Result PDF
